ストックスクリーナーアプリを入手
24.25
0.74%
-0.18
前日終値:
$24.43
開ける：
$24.6
24時間の取引高:
266.06K
Relative Volume:
0.78
時価総額：
$1.65B
収益：
$350.00K
当期純損益:
$-72.78M
株価収益率:
-22.45
EPS:
-1.08
ネットキャッシュフロー:
$-54.46M
1週間 パフォーマンス:
+18.24%
1か月 パフォーマンス:
+15.86%
6か月 パフォーマンス:
+39.41%
1年 パフォーマンス:
+33.39%
1日の値動き範囲:
$23.80
$24.73
1週間の範囲:
$21.30
$24.84
52週間の値動き範囲:
$12.56
$26.30
Pulse Biosciences Inc Stock (PLSE) Company Profile
Compare PLSE vs ISRG, BDX, MDLN, ALC, RMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PLSE
Pulse Biosciences Inc
|
24.25 | 1.63B | 350.00K | -72.78M | -54.46M | -1.08 |
ISRG
Intuitive Surgical Inc
|
478.82 | 160.28B | 10.58B | 2.99B | 2.49B | 8.2405 |
BDX
Becton Dickinson Co
|
154.85 | 44.57B | 21.92B | 1.76B | 2.63B | 6.1223 |
MDLN
Medline Inc
|
46.23 | 38.56B | 28.43B | 1.16B | 1.26B | 1.4457 |
ALC
Alcon Inc
|
75.86 | 37.93B | 10.40B | 980.00M | 1.61B | 1.9749 |
RMD
Resmed Inc
|
219.51 | 32.23B | 5.40B | 1.49B | 1.78B | 10.12 |
Pulse Biosciences Inc Stock (PLSE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-30 | 開始されました | Mizuho | Outperform |
| 2025-07-07 | 開始されました | Oppenheimer | Outperform |
| 2021-07-27 | 開始されました | Stephens | Overweight |
| 2021-03-11 | 開始されました | Maxim Group | Buy |
| 2021-01-26 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-05-12 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2020-02-14 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2019-02-25 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Pulse Biosciences Inc (PLSE) 最新ニュース
Pulse Biosciences Trials And Conference Spotlight Reframe Pulse Field Ablation Story - Yahoo Finance
Pulse Biosciences' nPulse Technology to be Featured at the Heart Rhythm Society 2026 Annual Meeting - Investing News Network
Pulse Biosciences (PLSE) to Showcase Innovations at Heart Rhythm Society 2026 Meeting - GuruFocus
Pulse Biosciences Starts US Trial for Cardiac Catheter System - HarianBasis.co
Pulse Biosciences (PLSE) Enrolls Its First Patients in a Pivotal Atrial Fibrillation Trial - Insider Monkey
Pulse Biosciences’ nPulse™ Technology to be Featured at the Heart Rhythm Society 2026 Annual Meeting - Business Wire
Total debt per share of Pulse Biosciences, Inc. – FWB:6L8 - TradingView
Pulse (PLSE) Stock: Is It Moving in a Trend (Breakout Watch) 2026-04-18Asset Allocation - Xã Vĩnh Công
Pulse Biosciences (NASDAQ:PLSE) Trading 10.1% HigherHere's Why - MarketBeat
Pulse Biosciences to Host Analyst Event on April 25, 2026 - The Joplin Globe
PLSE Stock Price, Quote & Chart | PULSE BIOSCIENCES INC (NASDAQ:PLSE) - ChartMill
Pulse Biosciences Targets Thyroid Nodules With New Device Study, Eyeing a Minimally Invasive Niche - TipRanks
Pulse Biosciences Updates 2026 Cardiac Ablation Strategy - TipRanks
Pulse Biosciences posts updated investor deck with pivotal nsPFA cardiac study details - TradingView
Pulse Biosciences (PLSE) updates investor deck with 2026 clinical goals - Stock Titan
Trading Systems Reacting to (PLSE) Volatility - Stock Traders Daily
Mizuho Securities Maintains Pulse Biosciences(PLSE.US) With Buy Rating, Maintains Target Price $30 - 富途牛牛
Income Plays: Does Pulse Biosciences Inc have strong fundamentalsPortfolio Update Summary & Reliable Price Breakout Signals - baoquankhu1.vn
Pulse Biosciences Initiates Patient Enrollment in NANOPULSE-AF Study - Yahoo Finance
Is Pulse Biosciences’ New Leadership Structure Reframing the PLSE Cardiac Therapy Commercialization Story? - Sahm
Pulse Biosciences Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Can Pulse Biosciences’ (PLSE) New AF Study and C-Suite Hires Reframe Its PFA Strategy? - Yahoo Finance
Q4 2025 Pulse Biosciences Inc Earnings Call Transcript - GuruFocus
Pulse Biosciences hires Liane Teplitsky as COO - MedTech Dive
Pulse Biosciences names Liane Teplitsky as chief operating officer By Investing.com - Investing.com Australia
Pulse Biosciences, Inc. (PLSE) stock price, news, quote and history - Yahoo Finance Singapore
Pulse Biosciences Strengthens Executive Leadership Team - Investing News Network
Pulse Biosciences appoints new COO to advance commercialization - TipRanks
Pulse Biosciences Appoints Liane Teplitsky as Chief Operating Officer Effective April 8, 2026 - Minichart
Liane R. Teplitsky named Chief Operating Officer at Pulse Biosciences - TradingView
Pulse Biosciences (PLSE) hires new COO with large inducement equity grants - Stock Titan
Pulse Biosciences Names Liane Teplitsky Chief Operating Officer - marketscreener.com
Pulse Biosciences strengthens executive leadership team - marketscreener.com
Pulse Biosciences names Liane Teplitsky as chief operating officer - Investing.com
Pulse Biosciences: Promising Catheter Technology, Weak Risk-Reward For Now - Seeking Alpha
Pulse Biosciences Stock Drops 13% In A Day, Why You Shouldn Not Be Buying The Stock - Trefis
How Low Can PLSE Really Go In A Market Crash? - Trefis
Pulse Biosciences Inc Enrolls First Patients in NANOPULSE-AF Ide Pivotal Clinical Study Evaluating nsPFA Cardiac Catheter System for Atrial Fibrillation - marketscreener.com
Pulse Biosciences Enrolls 1st Patient in nPulse PFA Tech Trial for AFib - Medical Product Outsourcing
Pulse Biosciences Inc (PLSE) Shares Gap Down to $19.14 on Apr 7 - GuruFocus
Pulse Biosciences begins pivotal atrial fibrillation trial By Investing.com - Investing.com South Africa
Pulse Biosciences Launches Pivotal NANOPULSE-AF Clinical Study - TipRanks
Pulse Biosciences, Inc. Files 8-K with SEC Detailing Company Information and Nasdaq Listing - Minichart
First patients treated in Pulse Biosciences (NASDAQ: PLSE) NANOPULSE-AF AFib trial - Stock Titan
Pulse Biosciences begins pivotal atrial fibrillation trial - Investing.com
Pulse Biosciences (NASDAQ: PLSE) recently announced that its pivotal clinical study of the Npulse™ Cardiac Catheter System for atrial fibrillation treatment (Nanopulse-Af Ide) has completed enrollment of the first group of patients. - Bitget
Pulse Biosciences enrolls first patients in Nanopulse-AF IDE pivotal clinical study evaluating nPulse(TM) cardiac catheter system for atrial fibrillation - marketscreener.com
Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation - TradingView — Track All Markets
PLSE SEC FilingsPulse Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Pulse Biosciences Inc (PLSE) 財務データ
収益
当期純利益
現金流量
EPS
0.55%
0.22%
大文字化:
|
ボリューム (24 時間):